Matrix metalloproteinases in type 2 diabetes and non-diabetic controls: Effects of short-term and chronic hyperglycaemia

Archives of Medical Science

Volumn 7, Issue 2, 2011, Pages 294-303

  Lewandowski, Krzysztof C ^a   Banach, Ewa ^b   Bieńkiewicz, Małgorzata ^a   Lewiński, Andrzej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b St Alexander City Hospital   (Poland)

Author keywords

Matrix metalloproteinases; Oral glucose tolerance test; Type 2 diabetes

Indexed keywords

CHOLESTEROL; GELATINASE A; GELATINASE B; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPERGLYCEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79956346124     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2011.22081     Document Type: Article

References (44)

1. Kannel WB, McGee DL. Diabetes and glucose tolerance as a risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979; 241: 120-6. (Pubitemid 9238733)
2. Ruderman NB, Haudenschild C. Diabetes as an atherogenic factor. Prog Cardiovasc Dis 1984; 26: 373-412. (Pubitemid 14170169)
3. Barthelemy O, Jacqueminet S, Rouzet F, et al. Intensive cardiovascular risk factors therapy and prevalence of silent myocardial ischaemia in patients with type 2 diabetes. Arch Cardiovasc Dis 2008; 101: 539-46.
4. Adler AI. UKPDS-modelling of cardiovascular risk assessment and lifetime simulation of outcomes. Diabet Med 2008; 25: 41-6. (Pubitemid 352020094)
5. Beaudeux JL, Giral P, Brukert E. Matrix metalloproteinases and atherosclerosis. Therapeutic aspects. Ann Biol Clin 2003; 61: 147-58.
6. Shah PK. Plaque disruption and thrombosis. Potential role of inflammation and infection. Cardiol Rev 2000; 1: 31-9.
7. Mun-Bryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab 1998; 18: 1163-72. (Pubitemid 28509829)
8. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metallo proteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002; 106: 1543-9.
9. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001; 89; 201-10.
10. Galis ZS, Sukhova GK, Lark MV, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-503. (Pubitemid 24379627)
11. Whalting C, McPheat W, Hurt-Camejo E. Matrix management assigning different role of MMP-2 and MMP-9 in vascular remodeling. Arterioscler Thomb Vasc Biol 2004; 24: 10-1. (Pubitemid 38082405)
12. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteinase-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998; 32: 368-72. (Pubitemid 28396484)
13. Planas AM, Sole S, Justicia C. Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after focal cerebral ischeamia. Neurobiol Dis 2001; 8: 834-46. (Pubitemid 33055599)
14. Montaner J, Alvarez-Sabin J, Molina CA, et al. Matrix metalloproteinase expression is related to haemorrhagic transformation after cardioembolic stroke. Stroke 2001; 32: 2762-7. (Pubitemid 33134461)
15. Portik-Dobos V, Anstadt MP, Hutchinson J, Bannan M, Ergul A. Evidence for a matrix metalloproteinases-induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes 2002; 51: 3063-8.
16. Chung AW, Hsiang YN, Matzke LA, McManus BM, van Breemen C, Okon EB. Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. Circ Res 2006; 99: 140-8. (Pubitemid 44297037)
17. Inada A, Nagai K, Arai H, et al. Establishment of a diabetic mouse model with progressive diabetic nephropathy. Am J Pathol 2005; 167: 327-36. (Pubitemid 43026090)
18. Han SY, Jee YH, Han KH, et al. An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy. Nephrol Dial Transplant 2006; 21: 2406-16. (Pubitemid 44644511)
19. McLennan SV, Martell SK, Yue DK. Effects of mesangium glycation on matrix metalloproteinase activities possible role in diabetic nephropathy. Diabetes 2002; 51: 2612-8. (Pubitemid 34827414)
20. Kadoglou NP, Daskalopoulou SS, Perrea D, Liapis CD. Matrix metalloproteinases and diabetic vascular complications. Angiology 2005; 56: 173-89. (Pubitemid 40404472)
21. Wall S, Sampson MJ, Levell N, Williams T, Murphy G. Elevated matrix metalloproteinase-2 and -3 production from healthy dermal fibroblasts in human diabetes. Br J Dermatol 2003; 149: 13-6. (Pubitemid 36966505)
22. Baugh MD, Gavrilovic J, Davies IR, Hughes DA, Sampson MJ. Monocyte matrix metalloproteinase production in type 2 diabetes and controls - a cross sectional study. Cardiovasc Diabetol 2003; 2: 3.
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9. (Pubitemid 15018832)
24. Belfiore F, Iannello S, Volpicelli G. Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels. Mol Genet Metab 1998; 63: 134-41. (Pubitemid 28453331)
25. Matsuda M, DeFronzo R. Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 1999; 9: 1462-70.
26. Koutsovasilis A, Protopsaltis J, Triposkiadis F, et al. Comparative performance of three metabolic syndrome definitions in the prediction of acute coronary syndrome. Intern Med 2009; 48: 179-87.
27. Signorelli SS, Malaponte G, Libra M, et al. Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripherial arterial disease. Vasc Med 2005; 10: 1-6. (Pubitemid 40667579)
28. Derosa G, D'Angelo A, Tinelli C, et al. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab 2007; 33: 129-34.
29. Papazafiropoulou A, Perrea D, Moyssakis I, Kokkinos A, Katsilambros N, Tentolouris N. Plasma levels of MMP-2, MMP-9 and TIMP-1 are not associated with arterial stiffness in subjects with type 2 diabetes mellitus. J Diabet Comp 2008, Dec 4 [Epub ahead of print].
30. Sampson M, Davies I, Gavrilovic J, et al. Plasma matrix metalloproteinases, low density lipoprotein oxidisability and soluble adhesion molecules after a glucose load in type 2 diabetes. Cardiovasc Diabetol 2004; 3: 7-14.
31. Nakaya R, Uzui H, Shimizu H, et al. Pravastatin suppresses the increase in matrix metalloproteinase -2 levels after acute myocardial infarction. Int J Cardiol 2005; 105: 67-73. (Pubitemid 41406362)
32. Rizzoni D, Porteri E, De Ciuceis C, et al. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-depentent diabetes mellitus. Hypertension 2005; 45: 659-65. (Pubitemid 40418362)
33. Bellosta S, Canavesi M, Favari E, et al. Lacidipine modulates the secretion of matrix metalloproteinase-9 by human macrophages. J Pharmacol Exp Ther 2001; 296: 736-43. (Pubitemid 32187341)
34. Sampson M, Wall S, Baugh M, et al. Monocyte matrix and ADAM metalloproteinases expression in type 2 diabetes after aspirin therapy. Diabetes Res Clin Pract 2006; 71: 45-51. (Pubitemid 41821142)
35. Kim MP, Zhou M, Wahl LM. Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implication for atherosclerotic plaque rupture. J Leukoc Biol 2005; 78: 195-201. (Pubitemid 40979958)
36. Weihrauch D, Lohr NL, Mraovic B, et al. Chronic hyperglycemia attenuates coronary collateral development and impairs proliferative properties of myocardial interstitial fluid by production of angiostatin. Circulation 2004; 109: 2343-8. (Pubitemid 38656871)
37. Polhill TS, Saad S, Poronnik P, Fulcher GR, Pollock CA. Short-term peaks in glucose promote renal fibrogenesis independently of total glucose exposure. Am J Physiol Renal Physiol 2004; 287: F268-73.
38. Death AK, Fischer EJ, McGrath KC, Yue DK. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 2003; 168: 263-9.
39. Lewandowski KC, Komorowski J, O'Callaghan CJ, et al. Increased circulating levels of matrix metalloproteinase -2 and 9- in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 1173-7. (Pubitemid 43357797)
40. Derosa G, Ferrari I, D'Angelo A, et al. Matrix metalloproteinase-2 and -9 levels in obese patients. Endothelium 2008; 15: 219-24.
41. Glowinska-Olszewska B, Urban M. Elevated matrix metalloproteinase 9 and tissue inhibitor of metallo - proteinase 1 in obese children and adolescents. Metabolism 2007; 56: 799-805. (Pubitemid 46734087)
42. Garg R, Chaudhuri A, Munschauer F, Dandona P. Hyperglycemia, insulin, and acute ischemic stroke: a mechanistic justification for a trial of insulin infusion therapy. Stroke 2006; 37: 267-73. (Pubitemid 43732090)
43. Boden G, Song WW. Effects of insulin and free fatty acids on matrix metalloproteinases. Curr Diabet Rep 2008; 8: 239-42.
44. Kappert K, Meyborg H, Clemenz M, et al. Insulin facilitates monocyte migration: a possible link to tissue inflammation in insulin-resistance. Biochem Biophys Res Commun 2008; 365: 503-8. (Pubitemid 350186280)